| Name | Title | Contact Details |
|---|
Hadron is a premier A- VIII rated international hybrid fronting carrier, dedicated to transforming the insurance landscape for SMEs and lower middle-market insureds. As a modern market entrant, Hadron boasts a robust backing of $250 million in capital, and a strategic partnership network within the Altamont family. Hadron is an unencumbered, clean insurance entity specializing in custom insurance solutions for todays risk landscape. Our commitment to excellence is demonstrated in our top-tier operational frameworks and cutting-edge technology built to exceed expectations of partners and clients.
Aegis Sortation is a technology and innovation leader specializing in the Freight and Parcel, Warehouse and Distribution, and E-Commerce industries. At Aegis we are innovating today to transform industries tomorrow! Innovation is the engine that drives our company forward and generates the creative forces behind everything we do and make. We are dedicated to providing exceptional service for our customers and exceeding industry standards for speed, durability, and safety. Our products are specifically designed to transform business; always, with no exceptions. This approach allows us to take advantage of both tried-and-true practices as well as applicable cutting-edge technologies. Aegis is determined to bring innovation, excellence and results to every project and partnership.
FedPoint® is a benefits marketplace operator and third-party administrator that serves millions of customers in the federal civilian and uniformed services markets. A wholly owned subsidiary of John Hancock Life & Health Insurance Company, FedPoint was founded in 2002 and is headquartered in Portsmouth, NH.
GEICO is a Maryland-based financial institution that provides personal and commercial insurance products for individuals and businesses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.